EP1906992A1 - Utilisation d' un melange de superoxyde dismutase et de catalase pour le traitement des lesions d origine inflammatoire de la peau - Google Patents
Utilisation d' un melange de superoxyde dismutase et de catalase pour le traitement des lesions d origine inflammatoire de la peauInfo
- Publication number
- EP1906992A1 EP1906992A1 EP05774360A EP05774360A EP1906992A1 EP 1906992 A1 EP1906992 A1 EP 1906992A1 EP 05774360 A EP05774360 A EP 05774360A EP 05774360 A EP05774360 A EP 05774360A EP 1906992 A1 EP1906992 A1 EP 1906992A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- use according
- superoxide dismutase
- catalase
- mixture
- sod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000019197 Superoxide Dismutase Human genes 0.000 title claims abstract description 62
- 108010012715 Superoxide dismutase Proteins 0.000 title claims abstract description 62
- 102000016938 Catalase Human genes 0.000 title claims abstract description 46
- 108010053835 Catalase Proteins 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 8
- 206010040882 skin lesion Diseases 0.000 title abstract 2
- 231100000444 skin lesion Toxicity 0.000 title abstract 2
- 230000003902 lesion Effects 0.000 claims abstract description 12
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 11
- 230000001969 hypertrophic effect Effects 0.000 claims abstract description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 6
- 208000001126 Keratosis Diseases 0.000 claims abstract description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 206010023330 Keloid scar Diseases 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 9
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 240000007124 Brassica oleracea Species 0.000 claims description 7
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 7
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 7
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 7
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 210000004207 dermis Anatomy 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 239000011859 microparticle Substances 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 241000228245 Aspergillus niger Species 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 240000003291 Armoracia rusticana Species 0.000 claims description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 3
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 claims description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 3
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 3
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 claims description 3
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 240000005979 Hordeum vulgare Species 0.000 claims description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 3
- 244000141359 Malus pumila Species 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 235000021016 apples Nutrition 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 244000241257 Cucumis melo Species 0.000 claims 2
- 244000098338 Triticum aestivum Species 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 206010051814 Eschar Diseases 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 3
- 230000002500 effect on skin Effects 0.000 abstract description 3
- 231100000333 eschar Toxicity 0.000 abstract description 3
- 208000032544 Cicatrix Diseases 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 235000013336 milk Nutrition 0.000 abstract description 2
- 239000008267 milk Substances 0.000 abstract description 2
- 210000004080 milk Anatomy 0.000 abstract description 2
- 239000011505 plaster Substances 0.000 abstract description 2
- 231100000241 scar Toxicity 0.000 abstract description 2
- 230000037387 scars Effects 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 7
- 241000219112 Cucumis Species 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 241000209140 Triticum Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108010078519 Extramel Proteins 0.000 description 1
- 239000008954 Extramel Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000442474 Pulsatilla vulgaris Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Definitions
- Fibroses are non-specific lesions that are characterized by hyperplasia of connective tissues with proliferation of fibroblasts or fibrocytes developing collagen. They cause the transformation into bundles composed mostly of connective tissue, following a pathological phenomenon or a therapeutic act.
- fibroblasts are temporally activated in myofibroblasts to proliferate and form the collagen matrix.
- Part of the dermis with fibrosis may somehow be considered as an area in which healing activating signals are emitted continuously, causing abnormal production of cytokines and growth factors, said abnormal production resulting in chronic and long-term activation.
- myofibroblasts then give a fibrosis.
- radiation including radiotherapy and free radicals are known and can be potentiated by chemotherapeutic treatments such as bleomycin.
- the keloid scar is a benign skin tumor that usually looks like a bulge and develops on scars. It is caused by uncontrolled growth of fibrous tissue that develops beyond the area to heal and does not regress after excision. This type of disruption of the healing process leads or may lead to hypertrophic pressure sores that appear when an imbalance appears between the anabolic and catabolic phases of the healing process, resulting in the production of collagen in a greater quantity than the degraded one and the growth of escapes in all directions.
- keloid scars and hypertrophic eschars occurs only when the lesions are mature, the histological difference being essentially the presence of keloid collagen in keloid scars.
- an inflammatory phase often appears in the form of erythema.
- the treatments are varied and are mainly preventive, we can mention bandages, compression during healing, corticosteroids, radiotherapy (very controversial) and interferon-based treatments.
- Surgical gestures are also widely practiced as well as cryosurgery and laser.
- Therapeutic trials based on the administration of active molecules affecting collagen synthesis have been performed among which proline-6-hydroxyproline, azetidine carboxylic acid, trinilast or molecules with antiallergic activity.
- the use of growth factors has also led to more or less satisfactory results.
- compositions for the prevention and treatment of damage caused by oxidation in the delivery phases circulating the heart after cardiac surgery, ischemic stroke or blood clots based on superoxide dismutase (SOD) and catalase (CAT) are known from US5080886.
- the present invention relates to the use of a mixture of superoxide dismutase and catalase for the preparation of a topical composition for the treatment of dermal fibrosis, epidermal keratoses, keloid scars or hypertrophic eschars.
- Superoxide dismutase is a stable enzyme of natural origin, it removes superoxide radicals without being consumed and is generally soluble in water. Superoxide dismutase is either of vegetable origin or obtained by biotechnology.
- Catalase is a ferriporphyrinic enzyme that catalyzes the release of molecular oxygen from hydrogen peroxide.
- Catalase protects the cell by attacking superoxide free radicals.
- SOD SOD
- copper / zinc SOD SOD
- manganese SOD SOD
- ferric SOD SOD
- SOD Cu / Zn protects the cytoplasm where free radicals are produced by metabolic reactions
- SOD Mn protects the mitochondrion of the cell containing genetic information and acting as the site of cellular energy production.
- the SOD can come from any origin. SOD is naturally present in most plants, it is found in extracts, apples, certain varieties of cabbage, broccolis, brussels sprouts, even possibly transgenic cabbage or melon and also horseradish, or it can be extracted from germs or grain sprouts rich in enzymes, such as wheat, corn, soy or barley
- bovine erythrocytes human
- microorganisms such as E. coli or yeasts
- mammalian livers it is potentially extracted from bovine erythrocytes, human, produced by recombinant synthesis by microorganisms such as E. coli or yeasts or also extracted from mammalian livers.
- the invention thus relates in one embodiment to a composition characterized in that the superoxide dismutase is obtained by biotechnology, for example from a natural strain of saccharomyces cerevisiae.
- SOD can be complexed or bound to polymers without prejudice to its enzymatic activity, for example polyethylene glycol or polysaccharides.
- Catalase which converts hydrogen peroxide into water and oxygen, can come from any origin.
- catalase can be obtained from mammalian liver extract or microorganisms such as Aspergillus Niger.
- These two enzymes may be encapsulated or incorporated into polymeric microparticles, for example consisting of crosslinked ionic polysaccharides and / or hydrophilic polymers.
- These two enzymes may be in freeze-dried form, for example powder, crystalline suspension or in the form of suspended ammonium sulphate.
- Extracts of melon, cabbage or mammalian livers contain these two associated enzymes, for example, extracts of melon, cabbage or mammalian livers.
- the SOD / CAT mixture that is original that is to say that the extract contains the mixture of the two enzymes at the extraction or that it has been prepared must allow to have an enzymatic activity ratio of between 14/2 and 15/5 with an enzymatic activity of SOD of between 10 000 and 16 000 IU per gram.
- the activity of the catalase will be between about 1500 and 4000 IU per gram.
- the enzymatic activity of SOD is determined by the method of Beauchamp C. and Fridovich I., Analytical Biochemistry 44, 276 (1971), modified by the method of Spitz, D., and Oberley, L .: An Assay for Superoxide This method is an indirect method because of the short life span of SOD; it makes it possible to evaluate SOD by its ability to inhibit a superoxide anion flux generated by the xanthine-xanthine oxidase system.
- catalase activity is determined by the method of ClaiBorne A., Catalase activity, CRC Handbook of Methods for oxygen radical research, 283-284, 1985.
- This method is based on the decomposition of hydrogen peroxide by catalase followed by UV spectrophotometry at 240 nm.
- the invention thus relates to the use of a mixture of superoxide dismutase and catalase for the preparation of a topical composition for the treatment of lesions of inflammatory origin of the skin.
- the lesions are selected from the group consisting of fibroses of the dermis, epidermal keratoses, keloid scars or hypertrophic bedsores. It relates to the use described above, characterized in that the superoxide dismutase is extracted from apples, cabbages, broccoli, Brussels sprouts, possibly transgenic sprouts or melon, possibly transgenic melons or horseradish. It relates to the use described above characterized in that the superoxide dismutase is extracted from germs or shoots of cereals rich in enzymes selected from wheat, corn, soy or barley.
- the superoxide dismutase is obtained by biotechnology. It relates to the use described above characterized in that the superoxide dismutase is obtained from a strain of saccharomyces cerevisiae.
- the superoxide dismutase is extracted from bovine or human erythrocytes or extracted from mammalian livers.
- the catalase is obtained from extracts of mammalian livers or extracts of microorganisms such as Aspergillus Niger It relates to the use described above characterized in that the catalase is obtained from plant extracts.
- polymers are chosen from polyethylene glycol or polysaccharides. It relates to the use described above characterized in that the catalase or superoxide dismutase alone or in mixture are encapsulated or incorporated into polymeric microparticles.
- polymeric microparticles consist of crosslinked ionic polysaccharides and / or hydrophilic polymers.
- catalase or the superoxide dismutase alone or as a mixture are in a freeze-dried powder form, in the form of a crystalline suspension, in the form of ammonium sulphate in suspension.
- the natural extract is selected from melon extracts, cabbage or livers of mammals.
- the SOD / CAT mixture has an enzymatic activity ratio of between 14/2 and 15/5 with an enzymatic activity of SOD of between 10 000 and 16 000 IU by gram.
- catalase is between about 1500 and 4000 IU per gram.
- the SOD / CAT mixture used is a mixture extracted from a variety of Brassica Napus.
- the enzymatic activity of SOD is evaluated by the method described above at about 14,000 IU per gram.
- mixture SOD / CAT is provided by a melon extract stabilized extract marketed under the Extramel brand by BIONOV.
- the enzymatic activity of SOD is evaluated by the method described above at about 14,000 IU per gram.
- the enzymatic activity of catalase by the method described above is evaluated at 2000 IU
- the SOD / CAT mixture is provided by a mixture comprising SOD and catalase derived from plant extracts marketed by BIOTICS RESEARCH Corporation.
- the enzymatic activity of SOD is evaluated by the method described above at about 14,500 IU per gram.
- the enzymatic activity of catalase by the method described above is evaluated at 2500 IU.
- the SOD / CAT mixture is provided by a mixture prepared according to the final enzymatic activity required, namely 14000 IU per gram for SOD and 3000 IU per gram for SOD catalase. extracted from Escherichia CoIi in the form of freeze-dried powder (2500 IU / mg) and catalase extracted from Aspergillus Niger in freeze-dried form (170 IU / mg).
- compositions according to the invention are formulated to obtain all the galenical forms conventionally used for the topical application of a composition on the skin. They are formulated for example in the form of milk, cream, lotion, plaster or patch, in the form of a stick or powder to be solubilized in water or physiological saline before use.
- compositions according to the invention may optionally contain various additives, such as suspending agents, emulsifiers, anionic, cationic, nonionic, amphoteric polymers, proteins, vitamins, surfactants, mineral or vegetable oils. , waxes, gums and / or silicone resins, thickening agents, acidifying or alkalizing agents, solvents, pH stabilizers, anti-UV agents, preservatives, antibacterials and antifungals, perfumes or other adjuvants usually used in cosmetics or dermatology.
- additives such as suspending agents, emulsifiers, anionic, cationic, nonionic, amphoteric polymers, proteins, vitamins, surfactants, mineral or vegetable oils. , waxes, gums and / or silicone resins, thickening agents, acidifying or alkalizing agents, solvents, pH stabilizers, anti-UV agents, preservatives, antibacterials and antifungals, perfumes or other adjuvants usually used in cosmetics or dermatology.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2005/001837 WO2007000619A1 (fr) | 2005-06-28 | 2005-06-28 | Utilisation d’un melange de superoxyde dismutase et de catalase pour le traitement des lesions d’origine inflammatoire de la peau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1906992A1 true EP1906992A1 (fr) | 2008-04-09 |
Family
ID=35134152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05774360A Withdrawn EP1906992A1 (fr) | 2005-06-28 | 2005-06-28 | Utilisation d' un melange de superoxyde dismutase et de catalase pour le traitement des lesions d origine inflammatoire de la peau |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090092591A1 (ja) |
| EP (1) | EP1906992A1 (ja) |
| JP (1) | JP2008543967A (ja) |
| CN (1) | CN101247824A (ja) |
| WO (1) | WO2007000619A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2318521A1 (en) * | 2008-07-10 | 2011-05-11 | Life Science Investments Ltd. | Use of a mixture of superoxide dismutase and catalase for treating pruritus and alleviating its symptoms |
| WO2011028567A2 (en) | 2009-09-02 | 2011-03-10 | Access Business Group International Llc | Composition and method for skin repair |
| CA2841075A1 (en) * | 2011-07-06 | 2013-01-10 | Yunfeng Lu | Multiple-enzyme nanocomplexes |
| CN104774812A (zh) * | 2014-10-09 | 2015-07-15 | 湖南一九生物科技有限公司 | 玉米胚芽中提取超氧化物歧化酶的加工方法 |
| CN107397689B (zh) * | 2017-07-12 | 2020-12-11 | 贵州九立德生物制药有限公司 | 一种用于皮肤护理的制剂及其制备方法 |
| CN108042796B (zh) * | 2018-01-04 | 2021-11-30 | 江西华文科创文化发展有限公司 | 一种清除自由基的组合物及其制备方法与应用 |
| FR3131196A1 (fr) * | 2021-12-29 | 2023-06-30 | Lsi Silderma Ltd | Composition pour le traitement et/ou la prévention de la réapparition des vergetures rosées |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2766303B2 (ja) * | 1989-04-13 | 1998-06-18 | 生化学工業株式会社 | グリコサミノグリカンで修飾されたスーパーオキシドジスムターゼ及びその製造法 |
| GB8919661D0 (en) * | 1989-08-31 | 1989-10-11 | Univ Alberta | Superoxide dismutase-catalase conjugates |
| US5080886A (en) * | 1990-01-05 | 1992-01-14 | Sterling Drug Inc. | Pharmaceutical compositions for the prevention and treatment of oxidant injuries |
| FR2716884B1 (fr) * | 1994-03-03 | 1996-10-04 | Bio Obtention Sc | Extrait protéique de cucumis melo à activité antioxydante et procédé de préparation, composition cosmétique ou pharmaceutique ou composition alimentaire contenant un tel extrait. |
| CA2215317C (en) * | 1995-03-24 | 2002-07-23 | Focal, Inc. | Reduction of adhesions using controlled delivery of active oxygen inhibitors |
| US5646025A (en) * | 1995-05-05 | 1997-07-08 | Novo Nordisk A/S | Scytalidium catalase gene |
| US7468195B2 (en) * | 2000-06-09 | 2008-12-23 | Crawford Healthcare Limited | Skin treatment preparation |
| JP2004256408A (ja) * | 2003-02-25 | 2004-09-16 | Nagase Chemtex Corp | 毛髪用洗浄剤及びこれを用いた毛髪の洗浄方法 |
| US20050025737A1 (en) * | 2003-07-30 | 2005-02-03 | Sebagh Jean Louis | Compositions containing melon extracts |
-
2005
- 2005-06-28 JP JP2008518988A patent/JP2008543967A/ja active Pending
- 2005-06-28 US US11/988,053 patent/US20090092591A1/en not_active Abandoned
- 2005-06-28 CN CNA2005800514108A patent/CN101247824A/zh active Pending
- 2005-06-28 EP EP05774360A patent/EP1906992A1/fr not_active Withdrawn
- 2005-06-28 WO PCT/IB2005/001837 patent/WO2007000619A1/fr active Application Filing
Non-Patent Citations (18)
| Title |
|---|
| ABU BAKR MOHAMMAD.BIN ZAKARIYYA AL-RAZI: "Kitaab-al-Haawi-fil-Tibb", vol. XXI, part I 1968, pages: 288 |
| ALI IBN-E-ABBAAS MAJOOSI: "Kaamil-al-Sena'ah", part II 2005, pages: 198 |
| DATABASE TKDL [online] "Safoof -e- Qissa", XP003029148, Database accession no. AA21/187K |
| DATABASE TKDL [online] "Tila Baraae Asaar-e- Judri", XP003029150, Database accession no. AH3/1414 |
| DATABASE TKDL [online] "Tila Bara-e- Aabla Judri", XP003029154, Database accession no. AH5/2117 |
| DATABASE TKDL [online] "Tila Bara-e- Jarab Wa Aasaar", XP003029149, Database accession no. MH1/3976 |
| DATABASE TKDL [online] "Tila Murdaar Sang", XP003029155, Database accession no. MH5/2925 |
| DATABASE TKDL [online] "Tila-e- Judree", XP003029151, Database accession no. BA4/2144 |
| DATABASE TKDL [online] "Ubtan Bara-e- Nishaan Aabla", XP003029153, Database accession no. AH5/2394 |
| DATABASE TKDL [online] "Zimaad Baraai Nishaan-e- Judri", XP003029152, Database accession no. AH5/1875 |
| MOHAMMAD AKBAR ARZANI: "Qaraabaadeen Qaadri", 1968, pages: 398 - 399 |
| MOHAMMAD AKMAL KHAN: "Qaraabaadeen Azam wa Akmal", 1909, pages: 522 |
| MOHAMMAD AKMAL KHAN: "Qaraabaadeen Azam wa Akmal", 1909, pages: 538 |
| MOHAMMAD AKMAL KHAN: "Qaraabaadeen Azam wa Akmal", 1909, pages: 566 |
| MOHAMMAD AZAM KHAN: "Ikseer Azam", vol. IV, 1872, pages: 361 |
| MOHAMMAD SHAREEF KHAN: "Ilaaj-al-Amraaz", 1921, pages: 344 |
| See also references of WO2007000619A1 |
| TUAN TAI-LAN ET AL: "The molecular basis of keloid and hypertrophic scar formation", MOLECULAR MEDICINE TODAY, ELSEVIER, CAMBRIDGE, GB, vol. 4, no. 1, 1 January 1998 (1998-01-01), pages 19 - 24, XP002482917, ISSN: 1357-4310, DOI: 10.1016/S1357-4310(97)80541-2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007000619A1 (fr) | 2007-01-04 |
| JP2008543967A (ja) | 2008-12-04 |
| US20090092591A1 (en) | 2009-04-09 |
| CN101247824A (zh) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0138931B1 (fr) | Composition dermatologique et son procede de preparation | |
| US6309656B1 (en) | Cosmetic and skin protective compositions | |
| EP1906992A1 (fr) | Utilisation d' un melange de superoxyde dismutase et de catalase pour le traitement des lesions d origine inflammatoire de la peau | |
| JP3467748B2 (ja) | 酸化防止能を持つメロン蛋白質抽出物、その調製方法、及び該抽出物を含有する化粧品、薬剤又は食品組成物 | |
| CH657987A5 (fr) | Composition anti-acneique a base de peroxyde de benzoyle et d'au moins un autre principe actif. | |
| EP0423002B1 (fr) | Composition antimicrobienne pour application sur la peau, applications comme déodorant corporel et bactéricide cutané | |
| FR2956818A1 (fr) | Utilisation d'un hydrolysat peptidique de lin dans une composition pour apaiser la peau | |
| US20070253943A1 (en) | Compositions for Topical Treatment | |
| CH669727A5 (ja) | ||
| EP0904054A1 (fr) | UTILISATION D'alpha-ALKYLGLUCOSIDES ET D'ESTERS D'alpha-ALKYLGLUCOSIDES EN TANT QU'AGENTS EMULSIONNANTS ANTI-MICROBIENS | |
| CN105456086B (zh) | 一种狗牙蔷薇果提取物的制备方法及其应用 | |
| EP0970691A1 (fr) | Produit pour application topique contenant une lipase, un précurseur de vitamine et un alcool gras | |
| EP0953345A1 (fr) | Utilisation d'au moins un hydroxystilbène en tant qu'agent diminuant l'adhésion des micro-organismes | |
| EP1129694B1 (fr) | Utilisation de composés permettant de modifier les propriétés physico-chimiques de la peau et/ou des muqueuses en tant qu'agents empêchant ou diminuant l'adhésion des micro-organismes sur ces dernières | |
| EP0909557B1 (fr) | Utilisation du miel en tant qu'agent diminuant l'adhésion des micro-organismes | |
| KR20170142632A (ko) | 여드름 치료 및 개선용 조성물 | |
| CA2252633A1 (fr) | Compositions cosmetiques et/ou pharmaceutiques et/ou dermatologiques | |
| US7468195B2 (en) | Skin treatment preparation | |
| FR2968955A1 (fr) | Composition cosmetique comprenant de l’acide ascorbique | |
| FR2938766A1 (fr) | Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat de feuille de vigne (vitis vinifera l.) en tant que principe actif activateur de l'aconitase et protecteur des mitochondries | |
| FR2604624A1 (fr) | Nouvelles compositions cosmetiques ou dermatologiques riches en acides gras essentiels presents a la fois sous forme de triglycerides et sous forme libre ou salifiee | |
| FR2609630A1 (fr) | Nouvelles compositions cosmetiques ou dermatologiques renfermant un extrait des fruits de silybum marianum riche en silymarine associe a des acides gras essentiels | |
| WO1997009958A1 (fr) | Produit cosmetique | |
| EP1286679B1 (fr) | Preparation a usage cutane | |
| EP4205758A1 (fr) | Superoxyde dismutase pour le traitement et/ou la prevention de la reapparition des vergetures rosees |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080121 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
| 17Q | First examination report despatched |
Effective date: 20080410 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120404 |